Science for Admin
Scientific Officer for Technology and Innovation
Conklin focuses on the genetic causes of severe human disease, such as cardiomyopathy and cardiac arrhythmia. He uses genome engineering methods to test the role of specific genetic changes in induced pluripotent cell-derived models of disease. These engineered human tissues are leading to safer drugs and better drug therapies. Conklin is also developing methods for therapeutic genome editing in select tissues.
Current projects use human induced pluripotent stem cells to model cardiac, hepatic. and retinal diseases. The Conklin laboratory has recently developed a method that significantly increases the ability of preform scarless single-base genome editing to induce or revert disease mutations. They have also developed CRISPR-inhibition cell lines for high-throughput gene inactivation screens. These studies allow the construction of robust in vitro human disease models and also provide a path towards precision medicine and therapeutic genome editing.